NOVAREMED
7.9.2021 10:02:10 CEST | Business Wire | Press release
Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its development programs, in an all-share transaction. The acquisition broadens Novaremed’s existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment, the Company’s focus area. Moreover, it enables Novaremed to target a wider spectrum of neuropathic pain indications, potentially also addressing broader applications by including prevention in addition to the treatment of pain. On the corporate side, Novaremed is strengthening its leadership team with a new board member, Andrew J. Oakley.
“The acquisition of Metys perfectly fits our strategy of pioneering the development of non-opioid pain treatments, aiming to deliver effective and well tolerated medications to patients while simultaneously addressing the urgent need for non-addictive treatments. I am delighted that industry expert Andrew Oakley is joining Novaremed’s Board of Directors and look forward to his support in the pursuit of our ambitious goals,” said Isaac Kobrin, Executive Chairman of the Board of Novaremed . “Our key objectives for the coming months are threefold: we plan to initiate the Phase 2b study with our promising lead candidate NDR.E1 for the treatment of painful diabetic peripheral neuropathy (PDPN), advance our new pipeline candidates from the Metys acquisition and, in parallel, will approach private and institutional investors to raise additional capital to support our pipeline which bears potential to provide next generation pain therapies.”
“I am pleased and excited about the acquisition of Metys by Novaremed as it represents a validation of our unique approach to the management of the progressive symptoms of peripheral sensory neuropathy. We have a clear pathway for our Phase 2 candidate MP-101 for the management of chemotherapy-induced painful symptoms of peripheral neuropathy, and our preclinical candidate MP-103 is being prepared for Phase 1,” said Michael Scherz, PhD, founder and Chief Executive Officer of Metys Pharmaceuticals . “We share the commitment to provide novel therapies to prevent, reduce or alleviate the burden of chronic pain and improve patient’s quality of life, thereby addressing an urgent unmet medical need and ultimately also reducing overreliance on opioids. Integrating Metys’ technologies and pipeline into Novaremed represents the best way forward towards accomplishing these goals.”
Broader pipeline of non-opioid development candidates
Going forward, Novaremed’s pipeline to address neuropathic pain will focus on three non-opioid development projects with entirely different modes of action:
NRD.E1 , an orally active small molecule with a novel mechanism of action and patent protection until 2040, acts as a Lyn kinase modulator and is the Company's lead compound being developed to treat PDPN. Novaremed successfully completed a double-blind, placebo-controlled Phase 2a dose-finding proof-of-concept study in which NRD.E1 showed a clinically relevant reduction in patient-reported pain (measured as an improvement in mean neuropathic pain score) and was very well tolerated at all doses tested. Moreover, the results suggested similar or greater pain relief, and better tolerability than reported for standard approved therapies. On the basis of these positive results, Novaremed is ready to proceed with a 12-week, double-blind, placebo-controlled Phase 2b study in patients with moderate to severe PDPN in the US, where it has an open IND and Fast Track Designation from the FDA.
MP-101 , a Phase 2 clinical candidate, is an orally available modulator of glutamate signaling. It works by preventing or reversing the ramped-up signaling that occurs in the spine and brain as a result of damaged peripheral nerves. MP-101 is a patented non-racemic mixture of the dimiracetam enantiomers with patent protection until 2039. In previous Phase 1 and Phase 2 clinical studies, in a total of 176 human subjects, a benign safety and tolerability profile comparable to placebo was noted for dimiracetam, and no signs or symptoms of sedation, dependence or withdrawal symptoms emerged. Based on pre-clinical proof of concept trials of chemotherapy-related neuropathy and pre-IND discussions with the FDA, MP-101 is being developed for the management of chemotherapy-induced neuropathy and neuropathic pain. The Phase 2 trial is expected to start in the first quarter of 2023.
MP-103 , a glutamate signaling modulator orally active in diverse rodent models for prevention and treatment of peripheral nerve injury symptoms, is set to start of Phase 1 clinical development in the first half of 2023.
Enlarged pipeline addresses a high unmet medical need with a wider indication focus
With its three development candidates, Novaremed seeks to address a wider spectrum of neuropathic pain, including the most common forms of painful diabetic peripheral neuropathy (PDPN) and chemotherapy-induced peripheral neuropathy (CIPN). Sensory symptoms of peripheral neuropathy, including neuropathic pain are highly prevalent conditions, and their incidence is rising as both diabetes and cancer become more frequent. 1 in 5 diabetes patients develops PDPN and half of them require treatment due to the severity of symptoms. In cancer, 4 in 5 patients undergoing neurotoxic chemotherapy develop CIPN, highlighting the necessity for early intervention or prevention. Novel treatments for these often debilitating and intractable chronic pain conditions are urgently needed due to limited efficacy and poor tolerability of many standard of care therapies. Importantly, Novaremed’s non-opioid pipeline also aims to address the high medical need for treatments without a risk of physical dependence and abuse, an inherent danger with commonly prescribed opioid-based therapies. Novaremed sees potential for its pipeline candidates beyond PDPN and CIPN and intends to evaluate opportunities in additional neuropathic pain indications, thereby further widening its initial indication focus.
Strengthening the leadership team
Andrew J. Oakley, Board member of Metys, will join the Board of Directors of Novaremed. He is an experienced pharmaceutical and biotech industry professional and currently serves as Chief Financial Officer of Autolus Therapeutics (NASDAQ: AUTL). Previously, he held CFO positions at listed pharmaceutical companies Sosei Group (TSE:4565), Vectura Group plc (LSE: VEC) and Actelion Ltd, where he led the finance function for over a decade. Before joining Actelion, Andrew held senior finance positions for Accenture as well as executive positions in major multinational building material companies. Andrew holds a Bachelor of Economics Degree from Macquarie University and an MBA from London Business School and has been a Member of the Australian Institute of Chartered Accountants since 1987.
About Novaremed
Novaremed AG, a privately held clinical-stage biopharmaceutical company, is innovating chronic pain management through the development of effective and safe treatment options as an alternative to opioids. Its lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, has FDA Fast Track Designation and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy (PDPN). The earlier stage pipeline addressing chronic pain includes the development candidates MP-101 (Phase 2 stage), targeting prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN), and MP-103 (preclinical stage). Novaremed’s clinical development portfolio aims to satisfy high medical patient needs and societal demands by alleviating the burden of pain associated with diabetes and cancer for patients and countering overreliance on addictive treatments. Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully-owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland). For more information: www.novaremed.com .
Read the full press release at www.novaremed.com or click here .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005360/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
